For the moments that should

make your
heart fill

A note to our patients: Our hearts go out to those most impacted by this virus, and we stand in solidarity with everyone navigating through this challenging and uncertain period. While the majority of our workforce is now sheltering in place, we at MyoKardia continue to work remotely to advance the treatment of cardiomyopathies.

driven by the heart

To change the world for people with serious cardiovascular diseases through bold and innovative science, we’re pioneering a precision medicine approach to treating cardiomyopathies and other forms of heart failure that results from biomechanical defects in cardiac muscle contraction.

Our Programs

Mavacamten

Obstructive HCM

Phase 3

Non-obstructive HCM

Phase 2

Targeted HFpEF

Phase 2

Mavacamten

Mavacamten is designed to address the excessive contractility, left ventricular hypertrophy and reduced compliance characteristic of hypertrophic cardiomyopathy (HCM).

Danicamtiv

Genetic Dilated Cardiomyopathy (DCM)

Phase 2

Systolic Dysfunction and Atrial Fibrilation

Phase 2

Danicamtiv

Danicamtiv is designed to increase contractility without impairing diastolic filling in patients with systolic heart failure.

MYK-224

HCM

Phase 1

MYK-224

MYK-224 is our second program targeting hypercontractility and impaired relaxation.

ACT-1

Precision Systolic Disease Indications

Preclinical

ACT-1

ACT-1 is our preclinical activator program directed toward increasing cardiac contractility in targeted dilated cardiomyopathy (DCM).

LUS-1

Precision Diastolic Disease Indications

Preclinical

LUS-1

LUS-1 is an emerging preclinical program targeting a muscle abnormality that results in impaired relaxation of the left ventricle.

We're all in because we all have a heart

scientific app r oach OUR FOR researchers patients FOR

news releases

see all news

we're hiring

Executive Director, Corporate Controller

Accounting

Marketing Manager

Marketing

Associate Director, Cinical Quality Assurance

Quality Assurance

see all openings

what's happening

BIO CEO & Investor Conference

Feb 11, 2020

Wear Red Day

Feb 07, 2020

Patient Visit

Jan 28, 2020

Life at MyoKardia
×

MyoKardia is a Bristol-Myers Squibb company

Select CONTINUE for information about Myokardia.

Select BMS to learn more about Bristol Myers Squibb.